Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Lexicon Pharmaceuticals

- PMLiVE

Novartis to acquire Tourmaline Bio in a deal worth $1.4bn

Novartis will gain cardiovascular treatment option pacibekitug

- PMLiVE

Novartis to expand cardiovascular pipeline with $3.1bn Anthos acquisition

The deal includes a candidate in phase 3 development to prevent complications of atrial fibrillation

- PMLiVE

Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn

The companies will advance therapeutics for undisclosed targets in Novartis’ core areas

- PMLiVE

Getting to the Heart of the Matter: Medscape Education at AHA 2024!

Come join Medscape Education at the American Heart Association (AHA) 2024 Scientific Sessions in Chicago, IL, from November 16-18 — a dynamic event packed with cutting-edge cardiology education that you...

Medscape Education

- PMLiVE

Medscape Education Wins Best Practice Award for Learner Outcomes at NAMEC

This year's winners have been announced  for the National Association of Medical Education Companies (NAMEC) awards. These awards recognize best practices-ideas or processes that can be implemented by NAMEC members to...

Medscape Education

- PMLiVE

Lexicon Pharma announces strong CV data for first-in-class sotagliflozin at the European Society of Cardiology’s annual meeting

The company will use data from the SOLOIST and SCORED trials as part of a new drug application later this year

- PMLiVE

Novo Nordisk gets MACE prevention claim for Ozempic in US

Key product for the future growth of Novo's diabetes franchise

Sanofi reception

Sanofi exits Zynquista alliance with Lexicon

Will pay $260m to end collaboration

- PMLiVE

AZ claims first-in-class win for Farxiga in heart failure

AZ in pursuit of class leader Jardiance

- PMLiVE

Amarin up as FDA speeds Vascepa’s cardiovascular claim review

Advance fuels takeover talk

- PMLiVE

Amgen, Servier heart failure drug clears trial hurdle

Drug could be a blockbuster - if it hits key endpoints

- PMLiVE

Sanofi gets cardio outcomes claim for Praluent in EU

Data stronger than rival's, could spark a fight back

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links